Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pegylated Liposomal Doxorubicin-contained Versus Daunorubicin-contained VDCLD Regimen in Previously Untreated Adult Patients With Acute Lymphoblastic Leukemia: Complete Remission Rates and Changes of Leukemia Stem Cells

NCT02070523 is registered in ClinicalTrials.gov with Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. as lead sponsor.

NCT NCT02070523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02070523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pegylated Liposomal Doxorubicin-contained Versus Daunorubicin-contained VDCLD Regimen in Previously Untreated Adult Patients With Acute Lymphoblastic Leukemia: Complete Remission Rates and Changes of Leukemia Stem Cells
Lead sponsor
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2013
Completion date
December 31, 2015
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia